203 related articles for article (PubMed ID: 31173789)
1. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
[TBL] [Abstract][Full Text] [Related]
2. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
5. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy.
Rodell CB; Ahmed MS; Garris CS; Pittet MJ; Weissleder R
Theranostics; 2019; 9(26):8426-8436. PubMed ID: 31879528
[TBL] [Abstract][Full Text] [Related]
6. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
8. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Rodell CB; Arlauckas SP; Cuccarese MF; Garris CS; Li R; Ahmed MS; Kohler RH; Pittet MJ; Weissleder R
Nat Biomed Eng; 2018 Aug; 2(8):578-588. PubMed ID: 31015631
[TBL] [Abstract][Full Text] [Related]
9. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy.
Kim H; Niu L; Larson P; Kucaba TA; Murphy KA; James BR; Ferguson DM; Griffith TS; Panyam J
Biomaterials; 2018 May; 164():38-53. PubMed ID: 29482062
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model.
Yin T; He S; Wang Y
Mol Med Rep; 2015 Sep; 12(3):3515-3520. PubMed ID: 26043701
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
Butchar JP; Mehta P; Justiniano SE; Guenterberg KD; Kondadasula SV; Mo X; Chemudupati M; Kanneganti TD; Amer A; Muthusamy N; Jarjoura D; Marsh CB; Carson WE; Byrd JC; Tridandapani S
Clin Cancer Res; 2010 Apr; 16(7):2065-75. PubMed ID: 20332325
[TBL] [Abstract][Full Text] [Related]
12. TLR7 and TLR8 agonist resiquimod (R848) differently regulates MIF expression in cells and organs.
Adzavon YM; Zhao P; Lv B; Liu M; Zhang X; Xie F; Yang L; Shang L; Zhang M; Li Q; Ma X
Cytokine; 2017 Sep; 97():156-166. PubMed ID: 28648870
[TBL] [Abstract][Full Text] [Related]
13. Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.
Ding Y; Liu J; Lu S; Igweze J; Xu W; Kuang D; Zealey C; Liu D; Gregor A; Bozorgzad A; Zhang L; Yue E; Mujib S; Ostrowski M; Chen P
J Control Release; 2016 Aug; 236():22-30. PubMed ID: 27297778
[TBL] [Abstract][Full Text] [Related]
14. IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod).
Jirmo AC; Daluege K; Happle C; Albrecht M; Dittrich AM; Busse M; Habener A; Skuljec J; Hansen G
J Immunol; 2016 Dec; 197(11):4219-4227. PubMed ID: 27799314
[TBL] [Abstract][Full Text] [Related]
15. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
[TBL] [Abstract][Full Text] [Related]
16. R848, a Toll-like receptors 7 and 8 agonist, a potential therapy for allergic rhinitis patients.
Boghdadi G; Hammad N; Amer A; Sammour S; Sorour S
Inflamm Allergy Drug Targets; 2014; 13(2):144-9. PubMed ID: 24773332
[TBL] [Abstract][Full Text] [Related]
17. TLR7/8 agonist treatment induces an increase in bone marrow resident dendritic cells and hematopoietic progenitor expansion and mobilization.
Li S; Yao JC; Li JT; Schmidt AP; Link DC
Exp Hematol; 2021 Apr; 96():35-43.e7. PubMed ID: 33556431
[TBL] [Abstract][Full Text] [Related]
18. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
Vasilakos JP; Tomai MA
Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
[TBL] [Abstract][Full Text] [Related]
19. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors.
Lee JH; Song J; Kim IG; You G; Kim H; Ahn JH; Mok H
Acta Biomater; 2022 Mar; 141():354-363. PubMed ID: 35007784
[TBL] [Abstract][Full Text] [Related]
20. TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells.
Jähnisch H; Wehner R; Tunger A; Kunze A; Oehrl S; Schäkel K; Rohayem J; Bornhäuser M; Tonn T; Bachmann M; Schmitz M
Cancer Lett; 2013 Jul; 335(1):119-27. PubMed ID: 23402811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
